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ABSTRACT
Decreased susceptibility of Staphylococcus aureus to antistaphylococcal agents may be associated with
inability to eradicate intracellular forms, which could explain therapeutic failures. This hypothesis was
tested using clinical isolates obtained from a patient with persistent staphylococcal bacteraemia under
therapy. Four isogenic isolates (three from tissue, one from blood) with increased MICs for vancomycin
(1–4 mg ⁄L) and for daptomycin (1–4 mg ⁄L) were collected after an initial 16-day treatment with
vancomycin–rifampicin–gentamicin, followed by 13–20 days of treatment with daptomycin–rifampicin–
gentamicin. Isolates were tested for MICs and for: (i) vancomycin (BODIPY-FL-vancomycin) and
daptomycin binding; (ii) cell wall turnover (loss of N-acetyl-D-[1-14C]glucosamine in 30 min after 1 h of
labelling); and (iii) Triton X-100-induced autolysis. Extracellular (broth) and intracellular (THP-1
macrophages) activities of rifampicin, linezolid and fusidic acid at Cmax, and of vancomycin,
daptomycin, quinupristin–dalfopristin and oritavancin over a wide range of extracellular concentrations
(with pharmacological modelling to determine Emax), were measured at 24 h. Increases in vancomycin
MICs correlated with increased drug binding, and decreased cell wall turnover and detergent-induced
autolysis. Increases in daptomycin MICs correlated with decreased daptomycin binding. Intracellular
activity was weak (Emax <1 log10 CFU decrease) for vancomycin against all isolates, and for daptomycin
against isolates with MICs >1 mg ⁄L. Among all antibiotics tested, only quinupristin–dalfopristin and
oritavancin provided close to bactericidal intracellular activities (1.6–2.5 log10 CFU decreases at Cmax).
Determination of the intracellular susceptibility of S. aureus, combined with improved methods of
diagnosis, could be useful when dealing with persistent staphylococcal infections and could improve
therapy.
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INTRODUCTION
Staphylococcus aureus is an aggressive pathogen
that poses a significant public health threat.
Treatment of staphylococcal diseases involves
two main challenges. First, this pathogen has
become increasingly resistant to currently avail-
able antibiotics, narrowing the choice of useful
agents [1–3]. In this context, vancomycin-interme-
diate S. aureus (VISA) isolates are being increas-
ingly encountered, although detection problems
with VISA and lack of agreement on definitions of
the hetero-VISA phenotype have complicated the
situation [4]. These strains appear to develop from
pre-existing methicillin-resistant S. aureus in
patients undergoing vancomycin therapy [5].
They are somewhat unique, owing to their
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increased cell wall thickness, the precise reason
for which is unknown but which is associated
with: (i) accumulation of free D-alanyl-D-alanine
termini in the peptidoglycan (acting as false target
sites for vancomycin [6,7]); and (ii) resistance to
detergent-induced autolysis [8]. Second, there is
growing evidence that S. aureus invades and
persists within eukaryotic cells [9,10]. This is
reflected clinically by its propensity to cause a
variety of recurrent and relapsing infections, such
as osteomyelitis, skin and skin structure infec-
tions, or endocarditis [11–13], offering an expla-
nation for the frequency and recurrence of such
invasive infections [9,14].
Although the metabolic and phenotypic char-
acteristics of laboratory-generated VISA have
been described by several groups [8,15,16], a
detailed analysis of isogenic strains has not been
frequently attempted [17]. Hence, this study
aimed to investigate the global properties of a
series of isogenic methicillin-resistant S. aureus
(MRSA) isolates recovered from a patient with a
prosthetic aortic valve who, as a complication of
bacteraemic pacemaker infection, developed an
endocardial abscess [18]. In addition, given that
the intracellular persistence of S. aureus may
reflect an important nidus for severe endocarditis,
the extracellular and intracellular activities of
several antibiotics commonly recommended or
under investigation for the treatment of staphylo-
coccal infections were also compared. Concen-
trating on macrophages, and using previously
established models [19,20], this study provides a
potential rationale for the poor clinical and micro-
biological response in patients infected with these
variants, while suggesting potential benefit in
using newly developed antistaphylococcal agents.
MATERIALS AND METHODS
Case report
The patient (a 65-year-old, with aortic valve replacement in
1991, coronary artery disease, sick-sinus syndrome, and
diabetes mellitus) was hospitalized for fevers that developed
2 weeks after pacemaker placement, with serosanguinous
discharge from the pacemaker site, and MRSA bacteraemia
(vancomycin MIC 2 mg ⁄L, daptomycin MIC 1 mg ⁄L). Details
on pertinent clinical events and therapeutic regimens in
relation to sample collection are presented in a synoptic
fashion in Table 1. Bacteraemia was documented over a 33-day
span, and resolved only after debridement of an abscess
underneath the aorta sewing ring and aortic valve replace-
ment, strongly suggesting that the maintenance of tissue foci of
infection was the main cause of the persistent character of the
infection. One year after discharge, the patient was clinically
well and showed no sign of relapse.
Table 1. Time course of the infection, successive antistaphylococcal therapies and vancomycin and daptomycin MICs for
Staphylococcus aureus isolated from the blood of the patient at the initiation of and during therapy
Day Event Antistaphylococcal treatment
MIC (mg ⁄L)a
Vancomycin Daptomycin
0 First hospitalization and blood sampling
Start of initial antibiotic treatment
Start vancomycin ⁄ gentamicin ⁄ rifampicin 2 1
6 Removal of pacemaker
13 Transfer to Hershey Medical Center
Isolation of VISA
4 1
15 Isolation of daptomycin-resistant S. aureus 2–4b 1–2b
16 Confirmation of vegetation on prosthetic aortic valve
Modification of initial treatment
Start daptomycin
Stop vancomycin and rifampicin
Continue gentamicin29 Isolation of VISA and daptomycin-resistant S. aureus 4–8c 4c
31 Change in antibiotic treatment Start linezolid
Stop gentamicin and daptomycin
35 Debridment of endocardial abscess; replacement of aortic valve;
sample collection from infected endocardial abscess
Transiently add vancomycin and gentamicin 2–8d 1–8d




49 Myalgia (related to quinupristin–dalfopristin) Stop quinupristin–dalfopristin
Continue linezolid
Add trimethoprim–sulphamethoxazole
65 Hyperkalaemia, renal failure Stop trimethoprim–sulphamethoxazole
Continue linezolid
77 End of antistaphylococcal treatment Stop linezolid
aDetermined at the Clinical Laboratory of the Hershey Medical Center (macrobroth dilution method and confirmed by microbroth and Etest methods); the values shown are
the extremes observed (see notes a–d).
bBetween day 11 and day 27, 14 isolates were obtained: one with vancomycin ⁄daptomycin MICs of 2 ⁄ 1 mg ⁄L, 12 with vancomycin ⁄daptomycin MICs of 4 ⁄ 1 mg ⁄L, and one
with vancomycin ⁄daptomycin MICs of 4 ⁄ 2 mg ⁄L.
cBetween day 29 and day 32, four isolates were obtained: one with vancomycin ⁄daptomycin MICs of 4 ⁄ 1 mg ⁄L, and three with vancomycin ⁄daptomycin MICs 8 ⁄ 4 mg ⁄L.
dOn day 35, nine isolates were obtained: eight with vancomycin ⁄daptomycin MICs of 2 ⁄ 1 mg ⁄L, and one with vancomycin ⁄daptomycin MICs of 8 ⁄ 8 mg ⁄L.
eAll blood cultures were negative for S. aureus (methicillin-resistant S. aureus or vancomycin-intermediate S. aureus (VISA)) as from day 36.
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Bacterial isolates and reference strains, and determination of
MICs and of agr polymorphism
The clinical isolates used in the present study (Table 2) have
been described previously [18]. In parallel, a fully sensitive
S. aureus strain (ATCC 25923) was used. A vancomycin-
intermediate S. aureus strain (NRS 126, obtained from
NARSA, Herndon, VA, USA (vancomycin MIC 4 mg ⁄L)) was
also used for control purposes. MICs were determined
independently at both institutions and yielded very similar
results. The methods used at the Hershey Medical Center have
been described in detail [18]. At the Universite´ catholique de
Louvain, a microdilution method was used, following the
recommendations of the CLSI, with both geometric and
arithmetic dilutions. For oritavancin, all media contained
0.002% polysorbate (Tween-80 or 2-(2-(3,4-bis(2-hydroxyeth-
oxy)oxolan-2-yl)-2-(2-hydroxythoxy)ethoxy)ethyl(E)-octadec-
9-noate) as advised by the manufacturer to prevent drug
binding to plastic. The accessory gene regulator (agr) poly-
morphism was determined by PCR [21,22].
Binding of vancomycin and daptomycin to whole bacteria
Drug binding was measured using boron dipyrromethene
difluoride-labelled vancomycin (BODIPYFL vancomycin;
Invitrogen Corp., Carlsbad, CA, USA) or unmodified dapto-
mycin. Bacteria were exposed to either drug (BODIPY-FL-
vancomycin, 1 mg ⁄L; daptomycin, 50 and 100 mg ⁄L) for
30 min at 37C in Mueller–Hinton Broth containing 2% NaCl
and adjusted to pH 7.4, harvested by centrifugation, washed
with ice-cold phosphate-buffered saline, and lysed as de-
scribed previously [23]. Both drugs were then assayed by
fluorimetry (Fluorocount TM (multiplate reader), Packard
Instruments, PerkinElmer Life and Analytical Sciences, Inc.,
Waltham, MA, USA), with excitation and emission wave-
lengths set at 485 and 530 nm for vancomycin (assay linearity:
0.6–4 mg ⁄L; R2 >0.99), and 380 and 425 nm for daptomycin
[24] (linearity: 1–250 mg ⁄L; R2 >0.99 (due to instrument
limitations, the optimal emission wavelength (460 nm) could
not be used, but this reduced the signal value by only c. 50%)).
Protein content was determined in parallel by using the Folin–
Ciocalteu ⁄ biuret method [25].
Autolysis assay
Triton X-100-stimulated autolysis in 50 mM glycine buffer
(pH 8) was assessed after 30 min following a previously
described protocol [17].
Cell wall turnover
Cells were labelled for 1 h at 37C with 5 lg of N-acetyl-D-
[1-14C]glucosamine (55 mCi ⁄mmol; Amersham plc, Little
Chalfont, Buckinghamshire, UK). After labelling, bacteria were
harvested by centrifugation and pellets were resuspended in
isotope-free medium containing 5 mM non-radioactive
N-acetyl-D-glucosamine [16], and collected either immediately
(time 0 h) or after 30 min of incubation at 37C. After being
washed in ice-cold phosphate-buffered saline, bacteria were
resuspended in 10% ice-cold trichloroacetic acid ⁄ 100 mM
N-acetyl-D-glucosamine [26], and radioactivity was measured
by liquid scintillation counting. Cell wall turnover was
expressed as the percentage of radioactivity released during
the 30-min post-labelling incubation period.
Determination of extracellular and intracellular activities
Extracellular activities were measured in broth as described
previously [27]. Intracellular activities were measured on bacte-
ria phagocytozed by THP-1 macrophages (ATCC TIB-202), a
human myelomonocytic cell line displaying macrophage-like
activity (American Tissue Collection; supplied through LGC
Promochem Ltd, Teddington, UK) as also described previously
([20,23]; the procedure used: (i) implies a 2000-fold dilution of
the cell samples on a volume basis, minimizing interference of
the carried-over antibiotic on CFU counting [28]; and (ii) limits
the incubation time for CFU counting to 24 h, so that the
occurrence of so-called ‘small-colony variants’ is not taken
into account [20]). Typical starting inocula were c. 1-2 ·
106 CFU ⁄mL (broth) or per mg of cell protein (macrophages).
Antibiotics and main reagents
The following antibiotics were obtained as microbiological
standards from their corresponding manufacturers: linezolid
Table 2. Clinical isolates, source of isolation and susceptibilities to selected antibiotics (all isolates are resistant to oxacillin,
ciprofloxacin, moxifloxacin, and rifampicin (see text)) in comparison with a fully sensitive reference strain
Isolate ⁄ straina Source of isolation
MIC (mg ⁄L)b
VAN TEC DAP LZD Q ⁄D FUS ORI
HMC 546
(#3)
Wound; aortic valvec 1 (1.25) 2 1–2 1 0.5 0.5 0.125
HMC 547
(#6)
Subvalvular tissuesc 2 (2) 4 3 1 0.5 0.5 0.125
HMC 548
(#10)
Annulus vegetationsc 4e (3.5) 8 4 1 0.5 0.5 0.5
HMC 549
(#17)
Bloodd 4e (4.0) 8 4 1 0.5 0.5 0.5
ATCC 25923 Reference strain 1 (0.9) 1–2 0.125–0.25 1 0.5 0.5 0.06
VAN, vancomycin; TEC, teicoplanin; DAP, daptomycin; LZD, linezolid; Q ⁄D, quinupristin–dalfopristin; FUS, fusidic acid; ORI, oritavancin.
aNumbers in parentheses are those used in the original description of the isolates [18].
bAs determined by geometric (log2 progression) dilution for all antibiotics by microdilution [20] (for vancomycin, numbers in parentheses refer to the MICs determined by
arithmetic dilutions using 0.25 mg ⁄L increments).
cIsolated at day 35 (see Table 1).
dIsolated at day 15 (see Table 1).
eDefined as vancomycin-intermediate S. aureus on the basis of the CLSI definition (MIC ‡2 mg ⁄L [52]); those isolates are, however, still considered susceptible according to
the EUCAST clinical breakpoints (£4 mg ⁄L; http://www.srga.org/eucastwt/MICTAB/MICglycopeptides.html) but fall 1 log2 dilution above the EUCAST epidemiological
cut-off (2 mg ⁄L; http://217.70.33.99/Eucast2/SearchController/regShow.jsp?Id = 13901).
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from Pfizer Inc., New York, NY; quinupristin–dalfopristin
(30 : 70 mass ratio) from Nordic Pharma, Paris, France; orita-
vancin from Targanta Therapeutics Corp., Cambridge, MA,
USA; daptomycin from Novartis AG, Basel, Switzerland;
teicoplanin from Sanofi-Aventis, Paris, France, rifampicin from
Merrell Dow Pharmaceuticals, Strasbourg, France; and cipro-
floxacin and moxifloxacin from BayerHealthCare, Leverkusen,
Germany. Gentamicin and vancomycin were obtained as the
corresponding branded products (Geomycin; Vancocin) as
distributed in Belgium (and complying with the provisions of
the European Pharmacopoeia for human use) by Glaxo-SmithK-
line s.a., Genval, Belgium (pilot studies showed that clinical
formulations and microbiological standards of these products
had similar activities). Oxacillin and fusidic acid were pur-
chased from Sigma-Aldrich, St-Louis, MO, USA. Cell culture
media and sera were from Invitrogen and other reagents from
Sigma-Aldrich or Merck KGaA, Darmstadt, Germany.
Statistical analyses
Curve-fitting analyses were made using GRAPHPAD PRISM ver-




Table 2 shows the clinical isolates used for the
present study with their anatomical source and
the MICs of selected antibiotics (all of these
isolates were resistant to oxacillin (MIC ‡16 mg ⁄L;
all strains carried the mecA and the SCCmec
group IVa genes), to fluoroquinolones (ciproflox-
acin MIC ‡32 mg ⁄L; moxifloxacin MIC ‡2 mg ⁄L)
and to rifampicin (MIC ‡4 mg ⁄L)). As compared
to the fully susceptible strain ATCC 25923 and
with the exception of strain HMC 546, all clinical
isolates also showed reduced susceptibility to
vancomycin and teicoplanin. Susceptibility to
daptomycin was also impaired, even for the
two vancomycin-susceptible S. aureus (VSSA)
strains (HMC 546 and HMC 547) and still more
for the two VISA strains. In contrast, the MICs
of fusidic acid, quinupristin–dalfopristin and
linezolid for all clinical isolates were low and
similar to those observed for ATCC 25923, and in
the same range as observed in a recent survey of
MRSA and VISA isolates [29]. For quinupristin–
dalfopristin, the MLSB phenotype was not estab-
lished, but the fact that VISA strains remain
susceptible to this antibiotic combination is not
surprising, as this has been observed in other
isolates, not only in our laboratory (Baudoux P,
Lemaine S, Van Bambebe F, Tulkens PU, unpub-
lished data) but also elsewhere [30,31]. For
oritavancin, MICs were two-fold to eight-fold
higher for the clinical isolates than for ATCC
25923 but still 2–3 log2 dilutions lower than those
of vancomycin.
Characterization of reduced susceptibility to
vancomycin
VISA strains have been reported to contain more
cell wall subunits able to bind vancomycin [7],
to have reduced cell wall turnover [16] and to
be more resistant to Triton X-100 autolysis [16]
in comparison with susceptible strains. These
characteristics were therefore examined for
four selected clinical isolates with different
susceptibilities to vancomycin (HMC 546 and
HMC 547 (VSSA) and HMC 548 and HMC 549
(VISA)). As shown in Fig. 1, vancomycin binding
increased, and cell wall turnover and Triton X-
100-induced autolysis decreased roughly in
parallel with the increase in MIC, consistent
with the concept that decreased susceptibility
to vancomycin is related to thickening of the
bacterial cell wall.
Earlier studies demonstrated that vancomycin
treatment failure is often associated with group II
polymorphism of the agr locus [32]. All clinical
isolates belonged to agr group II on the basis of
PCR analysis.
Characterization of daptomycin resistance
Because all clinical isolates (including the two
VSSA isolates HMC 546 and HMC 547) showed
MICs above the clinical susceptibility breakpoint
(1 mg ⁄L) of EUCAST and of the US labelling, the
binding of the drug to whole bacteria prepara-
tions from these isolates (HMC 546 and HMC
549) was measured in comparison with the fully
susceptible reference strain ATCC 25923 and a
reference VISA strain (NRS 126). As shown in
Fig. 2, binding of daptomycin (100 mg ⁄L) for both
clinical isolates was considerably reduced com-
pared to what was observed for the fully sensitive
strain and there was also a clear correlation
between reduced binding and increase in MIC
when all data points were considered (experi-
ments made at a daptomycin concentration of
50 mg ⁄L yielded values almost half of those
shown in Fig. 1, demonstrating that binding was
linear in the concentration span used).
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Assessment of the intracellular activities of
antibiotics
In earlier studies, the activity of antibiotics was,
generally speaking, markedly impaired intracel-
lularly as compared to what can be observed for
bacteria maintained in broth or in culture med-
ium [20,27,33]. As this phenomenon could explain
therapeutic failures in spite of acceptable suscep-
tibility as determined by conventional MIC mea-
surement, the extracellular and intracellular
activities of antistaphylococcal antibiotics towards
HMC 546 were systematically compared to the
fully susceptible ATCC 25923, using a model of
infected THP-1 macrophages.
In the first approach, all drugs were compared
at a reference concentration, which was arbitrarily
set at their observed or estimated Cmax (total
drug) when administered to humans at conven-
tional doses (rifampicin, 4 mg ⁄L; vancomycin,
50 mg ⁄L; daptomycin, 77 mg ⁄L; linezolid,
20 mg ⁄L; fusidic acid, 50 mg ⁄L; quinupristin–
dalfopristin, 10 mg ⁄L; oritavancin, 40 mg ⁄L).
The results are presented in Fig. 3, and show that
the loss of activity of all antibiotics when tested
against an intracellular form of S. aureus was as
important for the clinical isolates as for the
reference strain (the loss was marginal for fusidic
acid, but this antibiotic is essentially bacteriostatic
against both forms). For vancomycin, activity was
not much different between the reference strain
and HMC 546 and HMC 549, indicating that the
concentration used (50 mg ⁄L) was giving maxi-
mal activity, disregarding the differences in MIC.
In contrast, the decreased susceptibility of HMC
546 and HMC 549 to daptomycin in comparison
with the reference strain (MIC 1–2 vs. 0.12–
0.25 mg ⁄L) resulted in this drug almost comple-
tely losing its ability to kill intracellular bacteria,
even though it was used at a concentration
Fig. 1. Correlation between vancomycin susceptibility (MIC, as determined by arithmetic dilution) and vancomycin
binding (a), cell wall turnover (b) and Triton X-100-induced autolysis (c) of clinical isolates (from left to right in each graph:
HMC 546 (MIC 1.25 mg ⁄L); HMC 547 (MIC 2 mg ⁄L); HMC 548 (MIC 3.5 mg ⁄L), and HMC 549 (MIC 4 mg ⁄L)). All
values are means ± SD (n = 3; when not visible, SD bars are smaller than the symbols). The dotted lines show the result of a
linear regression analysis of each set of data. Values for the fully sensitive ATCC 25923 strain (MIC 1 mg ⁄L) were:
vancomycin binding, 4.3 ± 0.2 lg ⁄mg protein; cell wall turnover, 23.3 ± 0.3%; autolysis, 12.3 ± 0.2%.
Fig. 2. Correlation between binding of daptomycin
(100 mg ⁄L) to whole bacterial preparations (±SD (n = 3))
and MIC (as determined by geometric dilution (in dupli-
cate; no difference between individual values)) for (a) the
fully sensitive reference strain ATCC 25923
(MIC 0.125 mg ⁄L), (b) the vancomycin-intermediate Staph-
ylococcus aureus reference strain NRS 126 (MIC 0.5 mg ⁄L)
and the two clinical isolates (c) HMC 546 (MIC 1 mg ⁄L)
and (d) HMC 549 (MIC 4 mg ⁄L). The graph shows the
regression function obtained by fitting a sigmoid equation
to the data. Statistical analysis (ANOVA): data points with
different letters are significantly different from each other
(p <0.01).
770 Clinical Microbiology and Infection, Volume 14 Number 8, August 2008
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14, 766–777
much above its MIC (77 mg ⁄L). Quinupristin–
dalfopristin and oritavancin showed intermediate
activity. For oritavancin, this decrease was paral-
lel with its increase in MIC. Linezolid and fusidic
acid activities were essentially bacteriostatic in
macrophages, and their activities were not mark-
edly different between the clinical and the refer-
ence strains. Finally, the resistance of HMC 546
and HMC 549 to rifampicin in broth
(MIC 4 mg ⁄L) translated into a complete loss of
activity against its intracellular form when used at
that concentration. None of the antibiotics tested
had bactericidal activity against the intracellular
forms of either the reference or the clinical strains
(defined by a 3 log10 decrease of the cell-associ-
ated CFUs [34]), even though oritavancin ap-
proached it for ATCC 25923 and HMC 546, but
not for HMC 549. Fig. 4 shows the data of Fig. 3
expressed as a function of the concentration ⁄MIC
ratio for drugs with bactericidal effect in broth
(rifampicin, vancomycin, daptomycin, quinupri-
stin–dalfopristin, and oritavacin). It is clear that
the decrease in maximal intracellular activity is
c. 1.5–2 log10 CFU, and is reached once the con-
centration ⁄MIC ratio exceeds 50, independently
of the antibiotic–strain combination considered.
In this context, the lower response to daptomycin
and the lack of response to rifampicin of HMC
546 and HMC 549 are related to their lower
concentration ⁄MIC ratios.
To gain more insight into the concentration–
effect relationships of the antistaphylococcal anti-
biotics and the clinical isolates HMC 546 (VSSA)
and HMC 549 (VISA), in comparison with the
fully sensitive reference strain ATCC 25923
[20,27], full dose–response experiments were run
with vancomycin, daptomycin, quinupristin–
dalfopristin and oritavancin, using a wide range
of extracellular concentrations, spanning from
sub-MIC values to Cmax or above (vancomycin,
0.005–50 mg ⁄L; daptomycin, 0.01–250 mg ⁄L;
quinupristin–dalfopristin, 0.01–25 mg ⁄L; orita-
vancin, 0.01–40 mg ⁄L). The data were then used
to determine the corresponding Hill function
parameters. This approach allows an accurate
distinction between changes that affect drug
Fig. 3. Comparison between extracellular (broth; unhatched bars) and intracellular (THP-1 macrophages; hatched bars)
activities of antistaphylococcal antibiotics against the fully susceptible ATCC 25923 strain (white bars), the HMC 546
isolate (vancomycin-susceptible Staphylococcus aureus; light grey bars), and the HMC 549 isolate (dark grey bars). The
ordinate shows the change in the number of CFU (D log CFU) per mL of culture medium (broth) or per mg of cell protein
(THP-1). Each antibiotic was added for 24 h at a concentration corresponding to its known or estimated human serum Cmax
(total drug: rifampicin (RIF) 4 mg ⁄L; vancomycin (VAN) 50 mg ⁄L; daptomycin (DAP) 77 mg ⁄L; linezolid (LNZ) 20 mg ⁄L;
fusidic acid (FUS) 50 mg ⁄L; quinupristin–dalfopristin (Q ⁄D) 10 mg ⁄L; oritavancin (ORI) 40 mg ⁄L). The dotted horizontal
line shows the decrease in CFU (3 log10 units, commonly taken as an indication of a bactericidal effect [53].
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efficacy (by calculating the Emax parameter (rela-
tive efficacies)) and those that affect drug potency
(by calculating the corresponding EC50 parameter
(relative potency)) [20]. Data are presented graph-
ically in Fig. 5, and the corresponding Hill equa-
tion descriptors are presented in Table 3, together
with the regression parameters, an estimation of
the bacteriostatic concentration of each antibiotic
(Cs) and the Cmax ⁄Cs ratios. In all cases, activity
was related to concentration, conforming to the
pharmacological model previously described for
the reference strain [20]. This revealed significant
differences in relative efficacies (Emax), the abso-
lute values of which were significantly: (i) larger
for quinupristin–dalfopristin and oritavancin
than for vancomycin or daptomycin for all strains;
and (ii) lower for daptomycin when comparing
the two clinical isolates to the ATCC reference
strain. Interestingly, however, no statistically sig-
nificant difference in Emax was noted between
HMC 546 (VSSA) and HMC 549 (VISA) for each
of the antibiotics tested, indicating that the
reduced susceptibility of the VISA isolate to
vancomycin and daptomycin, as detected by the
measurement of MICs, was only relative (and
could be compensated for by an increase in
concentration). Differences in relative potencies
(EC50) were also noted between vancomycin and
daptomycin on the one hand, and quinupristin–
dalfopristin and oritavancin on the other (varia-
tions in the responses to oritavancin, however,
were not not statistically significant). Finally,
whereas the Cmax-to-bacteriostatic concentration
ratio ranking was clearly in favour of daptomycin
for the reference strain ATCC 25923, this ranking
became quinupristin–dalfopristin > vancomycin
 oritavancin  daptomycin for HMC 546
(VSSA), and quinupristin ⁄dalfopristin > orita-
vancin  daptomycin  vancomycin for HMC
549 (VISA).
DISCUSSION
Vancomycin has long been considered to be the
drug of choice for the treatment of MRSA infec-
tions. However, isolates of S. aureus with reduced
vancomycin susceptibility, first reported in Japan
[35], now appear to be widespread [5] and call for
both a better knowledge of the biochemical
changes associated with this phenotype (thereby
improving our diagnostic capabilities) and a
critical assessment of the proposed therapies.
The present article aims at extending our knowl-
edge of these strains in three main directions.
First, it was possible to correlate three critical
biochemical properties (binding of vancomycin,
cell wall turnover, and Triton X-100-induced
autolysis) with changes in vancomycin suscepti-
bility in a series of isogenic MRSA isolates
obtained from a single patient undergoing vanco-
mycin and daptomycin treatments given in suc-
cession [18]. This should allow for a more
confident interpretation of these altered proper-
ties, rather than examining variations occurring
for unrelated clinical isolates. Thus, the decrease
in susceptibility of the isolates collected during
treatment with vancomycin is directly correlated
with an increase in the drug binding to the bac-
teria, a reduction of the cell wall turnover, and a
decreased susceptibility to Triton X-100 autolysis.
Fig. 4. Extracellular and intracellular activities of rifampi-
cin, vancomycin, daptomycin, quinupristin–dalfopristin
and oritavancin against ATCC 25923, HMC 546 and
HMC 549 when plotted against the corresponding
Cmax ⁄MIC ratio (see Fig. 3 for activity and Cmax values
and Table 2 for MICs). Data were used to fit ‘one-phase
exponential decay’ functions (dotted line, intracellular
bacteria; solid line, extracellular bacteria) to help identify
the corresponding apparent maximal killing values
()1.6 log10 CFU for intracellular and )4.9 log10 CFU for
extracellular bacteria, as compared with the original
inoculum) and the Cmax ⁄MIC ratio at which these are
neared. The horizontal dotted line indicates the limit of
reliability of bacterial counts by the technique used (see
[20] for details). The real maximal killing activity against
extracellular bacteria could, therefore, be more extensive
than estimated here.
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This supports the concept that the VISA pheno-
type developing in vivo is due to bacteria building
up an ‘antibiotic-trapping’ mechanism through
the thickening of the cell wall [6], which eventu-
ally prevents vancomycin from diffusing and
reaching its lipid II target at the septal tip of
dividing bacteria [36]. Combined with the detec-
tion of agr group II polymorphism (more frequent
in VISA strains [37] and predictive of vancomycin
treatment failures [32]), these biochemical charac-
teristics could be useful in improving the early
and reliable diagnosis of VISA isolates in clinical
samples. Further studies using more clinical and
laboratory strains, however, will be needed to
confirm these correlations with the alterations in
susceptibility, and to fully demonstrate the spec-
ificity and selectivity of these biochemical
changes. Moreover, because these binding exper-
iments or cell wall turnover measurements are
difficult to implement in routine practice, more
simple tests will need to be developed. This
may actually become critical, given the present
situation of poor recognition of the reduced
susceptibility of S. aureus to vancomycin using
available automated commercial devices, espe-
cially in cases of heterogeneously resistant phe-
notypes [38].
Second, the rapid emergence of resistance to
daptomycin, already observed by others [39], is
puzzling. The isolates studied here had both cell
wall changes (reduction in muramic acid
O-acetylation) and point mutations (in mprF,
encoding lysylphosphatidylglycerol synthase)
[18]. Previous studies have shown that whole
cells and membranes of daptomycin-resistant
S. aureus bind a reduced amount of daptomycin
[40]. The present results confirm and expand this
observation, in that increases in daptomycin MICs
correlate with an almost commensurate reduction
of drug binding to the bacteria (as assessed by
fluorometric determination). A very recent study,
of which we became aware during the revision
process [41], has also identified a number of
additional changes in daptomycin-resistant
Fig. 5. Activities of four selected antibiotics (vancomycin (VAN); daptomycin (DAP); quinupristin–dalfopristin (Q ⁄D);
oritavancin (ORI)) against the intracellular forms of the reference, fully sensitive strain ATCC 25923 (open circles) and of
the two clinical isolates, HMC 546 (vancomycin-susceptible Staphylococcus aureus; open squares) and HMC 549
(vancomycin-intermediate S. aureus; closed squares) after phagocytosis by THP-1 macrophages. Cells were incubated with
the antibiotic for 24 h at the concentrations (total drug) indicated on the abscissa (VAN, 0.005–50 mg ⁄L; DAP, 0.01–
250 mg ⁄L; Q ⁄D, 0.01–25 mg ⁄L; ORI, 0.01–40 mg ⁄L). The graphs show the change in the number of CFUs (D log CFU) per
mg of cell protein. All values are means ± SD (n = 3; when not visible, the SD bars are smaller than the size of the symbols).
Data were used to fit sigmoid dose–response curves using a standard model with a slope factor (Hill coefficient) of 1 (see
Table 3 for regression parameters). The horizontal dotted line corresponds to a bacteriostatic effect (no net change from the
initial post-phagocytosis inoculum); the vertical dotted line indicates the extracellular concentration (total drug)
corresponding to the observed or estimated serum Cmax in patients receiving conventional dosages of the corresponding
antibiotic and used for the comparison of activities shown in Fig. 3.
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isolates (affecting membrane fluidity, transloca-
tion of the positively charged phospholipid lysyl-
phosphotidylglycerol to the outer membrane
leaflet, surface charge, susceptibility to daptomy-
cin-induced depolarization, permeabilization, and
autolysis), which will need to be explored in our
strains. Decreased daptomycin susceptibility in
VISA isolates is commonly ascribed to the
thickening of the cell wall, which shields the
daptomycin target (phophatidylglycerol) [7].
Although this could explain the decreased dap-
tomycin binding seen with HMC 548 or HMC
549, it probably cannot account for our observa-
tions with HMC 546, as this isolate was vanco-
mycin-susceptible and showed no increase in
vancomycin binding or decreased susceptibility
to detergent-induced autolysis. Therefore, a true
reduction of target abundance or shielding
through a mechanism other than cell wall
thickening is dealt with here. This will need to
be explored in more detail.
Third, although primarily known as an extra-
cellular pathogen, S. aureus has been shown to
invade and survive within the eukaryotic intra-
cellular environment [12,42]. Persistence in tissue,
most likely intracellularly, probably accounts for
several aspects of relapsing staphylococcal dis-
eases, long-term colonization, and persistence of
bacteraemia. Previous studies using reference
strains of S. aureus with various susceptibility
phenotypes [20,34] showed that conventional
antistaphylococcal agents are considerably less
efficient against intracellular bacteria than against
their extracellular counterparts. The present study
extends this concept to clinical strains and shows
that the pharmacological model derived from the
analysis of the reference strain ATCC 25923 is
also valid for these strains. In all cases, the lack of
bactericidal effect of the antistaphylococcal agents
against intracellular bacteria could be ascribed to
a loss of relative efficacy (Emax), explaining why a
large intracellular inoculum could persist regard-
less of the extracellular concentration of the
antibiotic [20,34]. Moreover, (i) a minimal extra-
cellular concentration ⁄MIC ratio of 50 is probably
necessary for near-maximal antibacterial effect;
and (ii) even for highly bactericidal antibiotics
such as oritavancin, quinupristin–dalfopristin, or
rifampicin, little or no improvement is expected
by further increasing the drug concentration ⁄MIC
ratio. The present study used macrophages,
which may be only partly representative of the
intracellular nidus seen in typical staphylococcal
infections (which, beyond macrophages, involve
keratinocytes [13], osteoblasts [11], or endothelial
cells [12]). However, it may allow us to draw two
important conclusions relative to potential treat-
ment failures such as those seen with the patient
presented in this study. First, a phenotype of
resistance to rifampicin (MIC ‡4 on the basis of
current CLSI breakpoints; EUCAST breakpoints
are 0.06 (S) and 0.5 (R)) makes the drug com-
pletely inactive against the intracellular forms of
S. aureus, even if used at a concentration that
corresponds to the MICs for extracellular bacteria.
This was surprising, as rifampicin accumulates in
macrophages (c. 20-fold in the model used here
[20]), and its activity is known to be enhanced by
Table 3. Pertinent regression parameters, statistical analysis and calculation of bacteriostatic concentrations from the
dose–response curves illustrated in Fig. 2
Antibiotic Strain




concentration ratioEmax (mg ⁄L)c,d EC50 (mg ⁄L)d,e R2
Vancomycin ATCC 25923 )0.87 ()1.14 to )0.60) a,A 0.99 (0.62–1.59) a,A 0.995 2.9 17
HMC 546 )0.87 ()1.27 to )0.47) a,A 1.33 (0.70–2.51) a,A 0.979 3.1 16
HMC 549 )0.68 ()1.32 to )0.04) a,A 3.79 (1.47–9.78) a,A 0.974 12 4.2
Daptomycin ATCC 25923 )1.64 ()2.04 to )1.26) b,B,E 1.13 (0.59–2.16) a,A 0.980 1.4 55
HMC 546 )0.61 ()1.16 to )0.06) a,A 3.20 (1.66–12.5) a,A 0.971 20 3.8
HMC 549 )0.59 ()1.14 to )0.05) a,A 4.56 (1.11–9.16) a,A 0.967 14 5.4
Quinupristin–dalfopristin ATCC 25923 )2.42 ()3.27 to )1.58) a,C,E 0.34 (0.12–0.94) a,C 0.973 0.46 21.7
HMC 546 )2.01 ()2.25 to )1.78) a,C,E 0.16 (0.11–0.25) a,C 0.995 0.19 53
HMC 549 )1.82 ()2.24 to ).50) a,C,E 0.26 (0.05–1.27) a,C,E 0.934 0.38 26
Oritavancin ATCC 25923 )2.46 ()3.50 to )1.42) a,C 2.95 (1.02–8.49) a,A 0.976 2.6 15
HMC 546 )2.54 ()3.79 to )1.57) a,C 3.24 (0.93–11.2) a,A 0.967 2.7 15
HMC 549 )1.61 ()2.44 to )0.77) a,C,B 1.51 (0.46–4.81) a,A,D 0.968 2.0 20
aStatistical analysis (one-way ANOVA; Tukey’s test for multiple comparisons): values with different letters are significantly different from each other within the pertinent
comparison group (p <0.05); lower-case letters, comparison between the three isolates for each condition (antibiotic); upper-case letters, comparison throughout all conditions.
bConcentration (mg ⁄L) resulting in no apparent bacterial growth (the number of CFU was identical to that of the original inoculum), as determined by graphical interpolation.
cCFU decrease (in log10 units) at 24 h from the corresponding original inoculum, as extrapolated for antibiotic concentration at infinity.
dTotal drug.
eConcentration (mg ⁄L) causing a reduction of the inoculum halfway between the initial (E0) and the maximal (Emax) values, as obtained from the Hill equation (by using a
slope factor of 1).
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acid pH (c. 30-fold decrease in MIC for ATCC
25923 [20]). Second, reduced susceptibility to
vancomycin (MIC >2 mg ⁄L [38]; see also the
current CLSI breakpoint) or to daptomycin
(MIC >1 [38]; see also the CLSI and the EUCAST
breakpoints) makes both drugs poorly active
against intracellular forms, even if used at extra-
cellular concentrations far above their MIC. The
accumulation of vancomycin and daptomycin in
cells infected by HMC 546 or HMC 549 was not
measured in comparison with those infected with
ATCC 25923. The possibility that the decreases in
intracellular activity observed for HMC 546 and
HMC 549 are due to pharmacokinetic parameters
(decreased accumulation) only cannot, therefore,
be excluded. However, differences in pharmaco-
dynamic parameters, related to target modifica-
tions, are more likely. Whatever the mechanism,
however, it is tempting to speculate that the low
intracellular efficacies of rifampicin, vancomycin
and daptomycin against the clinical isolates stud-
ied here is the reason why infection could not be
cured in the patient from whom the samples were
obtained, and why the infected tissues eventually
had to be surgically removed. It would be
interesting, in this context, to examine the effects
of drug combinations against the intracellular
forms of the clinical strains of this patient, as
combinations are known to be synergistic against
susceptible strains [43]. This is probably most
critical for vancomycin and daptomycin, because
the pharmacological analysis (Fig. 5) shows that:
(i) vancomycin has only limited efficacy against
all strains; and (ii) daptomycin maximal efficacy
is reduced against strains with an elevated MIC,
in a manner than cannot be compensated for by
an increase in its concentration.
This study also shows that fusidic acid, which
in many countries is considered to be a useful
resource for difficult-to-treat MRSA infections
caused by organisms requiring MICs of <1 or
2 mg ⁄L [44], is actually poorly effective against
intracellular forms. Conversely, quinupristin–
dalfopristin and oritavancin were quite active
against the intracellular forms of all clinical
isolates tested, regardless of their resistance phe-
notype. The approach used, however, did not
allow exclusion of the occurrence of the so-called
‘small-colony variants’ [45], a point that will be
examined in further studies. Given this limitation,
the superiority of oritavancin, as compared with
vancomycin, especially against VISA strains, is
consistent with its dual mode of action, which
involves not only its binding to D-Ala-D-Ala
motifs, e.g. vancomycin, but also transglycosylase
inhibition and membrane depolarization and
permeabilization [46]. The mode of action of
quinupristin–dalfopristin, for which synergism
between the two components is due to induction
of an increased ribosome affinity [47], is less
suggestive, apart from the fact that this combina-
tion of streptogramins is bactericidal in broth,
whereas single components are bacteriostatic
only. Quinupristin–dalfopristin and oritavacin
accumulate to large extents in cells [48,49], which
could suggest that their superior activity against
intracellular bacteria is mainly linked to this
specific cellular pharmacokinetic parameter.
Previous studies, however, show that there is no
simple correlation between cellular accumulation
and activity in the model used here when com-
paring a large number of antibiotics of different
pharmacological classes [20]. A role of carried-
over antibiotic (causing an artefactual decrease of
CFU counts) can also be excluded, on the basis of
the procedure used and considering that intracel-
lular activity reaches a plateau even if the con-
centration ⁄MIC ratio is increased to very large
values (Fig. 4).
This model has many limitations, which have
been discussed in detail in previous reports
[20,34], e.g. the use of a constant exposure to the
antibiotics, the impossibility of evaluating the
influence of the inhibitory effect of protein bind-
ing on drug efficacy, the limited duration of drug
exposure, and the many uncertainties concerning
relevance to the in vivo situation. For some of the
antibiotics, full dose–response curves were not
established, limiting the conclusions concerning
what has been observed at a concentration corre-
sponding to the human Cmax (total drug). All
these aspects will need to be carefully studied in
the future. For instance, the fact that aminoglyco-
sides penetrate cells only very slowly [50] makes
this model, although superior to other shorter-
term models, insufficient for true assessment of
the long-term effects of these drugs [51]. It may,
nevertheless, prove useful for a comparative
assessment of antistaphylococcal drugs and for
characterization of better agents in the future.
Combined with the improved diagnostic methods
suggested above, an assay of intracellular
activity could also contribute, already today, to
improved choices of appropriate therapies among
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available agents for difficult-to-treat staphylococ-
cal infections when persistence of intraphagocytic
S. aureus is suspected.
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